Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TWT's (Third Wave Technologies') Invader technology sensitivity confirmed:

This article was originally published in Clinica

Executive Summary

Third Wave Technologies' (TWT) RNA Invader technology, claimed to be a cost-effective alternative to PCR, can detect changes in gene expression level as small as 20%, according to an assessment published in the July issue of Nature Biotechnology. The assessment, by TWT (Madison, Wisconsin), also confirmed that Invader assays can routinely detect as few as 6,000 copies of RNA, and can detect a single target sequence in a pool of more than 20,000 sequences of closely related RNA. TWT has licensed the technology to Dade Behring.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT072076

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel